Global Peptide Therapeutics Market 2016-2020 - Product Image

Global Peptide Therapeutics Market 2016-2020

  • ID: 3633324
  • Report
  • Region: Global
  • 81 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Hanmi Pharmaceutical
  • Merck
  • PeptiDream
  • SciClone
  • MORE
About Peptide Therapeutics

Peptides are organic compounds that are composed of amino acids linked chemically by peptide bonds. They are the most potent biologically active substances found in nature and are used to trigger, control, and maintain an individual's physiological processes. However, using peptides as therapeutic agents was always difficult as they are quite instable and cannot pass through cellular membranes. They also require a specific technology to tackle extensive and challenging steps in their synthesis. Over 80 peptides are marketed by companies that explore the probabilities of designing and engineering peptides that can overcome their natural limits. They can be introduced as a treatment for chronic indications.

The analysts forecast the global peptide therapeutics market to grow at a CAGR of 7.92% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global peptide therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of prescription and generic drugs used to treat diseases.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Peptide Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Eli Lilly
- Novo Nordisk
- Sanofi
- Takeda Pharmaceutical
- Teva Pharmaceuticals

Other prominent vendors
- AbbVie
- Advanced Accelerator Applications
- Akashi Therapeutics
- Amgen
- Anthera Pharmaceuticals
- AstraZeneca
- Bachem
- Bristol-Myers Squibb
- Cardiorentis
- Corden Pharma International
- Debiopharm
- Derma Sciences
- GlaxoSmithKline
- Hanmi Pharmaceutical
- Insmed
- Ipsen
- Johnson & Johnson
- Lonza
- Mallinckrodt
- MolMed
- Merck
- Novartis
- Nymox Pharmaceutical
- Par Pharmaceuticals
- PeptiDream
- Polypeptide Group
- Radius Health
- Repligen
- Roche
- SciClone
- Shire
- The Medicines Company
- Transition Therapeutics
- X-Gen Pharmaceuticals
- Zealand Pharma
- Zydus Cadila

Market drivers
- Increase in patient population
- For a full, detailed list, view the full report

Market challenges
- High cost of therapy
- For a full, detailed list, view the full report

Market trends
- Shifting focus toward untapped markets
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Hanmi Pharmaceutical
  • Merck
  • PeptiDream
  • SciClone
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Overview of peptides
  • Peptide synthesis
  • Optimization of peptides
  • Stabilization of peptides
PART 06: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 07: Market segmentation based on route of administration
  • Parenteral
  • Oral
  • Pulmonary
  • Mucosal
PART 08: Market segmentation by drug class
  • Somatostatins
  • Vasopressin
  • Calcitonins
  • Luteinizing hormone (LH)-releasing hormone (LHRH)
  • Glucagon and analogs
  • Insulins
  • Other
PART 09: Market segmentation by synthesis technology
  • Liquid-phase peptide synthesis
  • Solid-phase peptide synthesis
  • Hybrid peptide synthesis
PART 10: Geographical segmentation
  • Global peptide therapeutics market segmentation by geography 2015-2020
  • Peptide therapeutics market in Americas
  • Peptide therapeutics market in EMEA
  • Peptide therapeutics market in APAC
PART 11: Market drivers
  • Increase in patient population
  • Advances in peptide synthesis technology
  • Promising pipeline
  • Unmet medical needs
  • Increase in healthcare spending
PART 12: Impact of drivers

PART 13: Market challenges
  • High cost of therapy
  • Adverse side effects
  • Stringent regulatory compliances
  • Intense market competition
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Growing popularity
  • Shifting focus toward untapped markets
  • Contract manufacturing
  • Increase in public awareness
PART 16: Vendor landscape
  • Competitive scenario
  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: SWOT analysis: Peptide therapeutics
Exhibit 03: Steps involved in peptide synthesis
Exhibit 04: Optimization of peptide synthesis
Exhibit 05: Methods used to stabilize peptides
Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
Exhibit 10: Global peptide therapeutics market segmentation by drug class
Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
Exhibit 25: Eli Lilly: Key takeaways
Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
Exhibit 40: Sanofi: Key takeaways
Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
Exhibit 45: Takeda Pharmaceutical: Key takeaways
Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
Exhibit 47: Teva Pharmaceuticals: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • Hanmi Pharmaceutical
  • Merck
  • PeptiDream
  • SciClone
  • MORE
New Report Released: – Global Peptide Therapeutics Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Peptide Therapeutics Market: Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, and Teva Pharmaceuticals.

Other Prominent Vendors in the market are: AbbVie, Advanced Accelerator Applications, Akashi Therapeutics, Amgen, Anthera Pharmaceuticals, AstraZeneca, Bachem, Bristol-Myers Squibb, Cardiorentis, Corden Pharma International, Debiopharm, Derma Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Insmed, Ipsen, Johnson & Johnson, Lonza, Mallinckrodt, MolMed, Merck, Novartis, Nymox Pharmaceutical, Par Pharmaceuticals, PeptiDream, Polypeptide Group, Radius Health, Repligen, Roche, SciClone, Shire, The Medicines Company, Transition Therapeutics, X-Gen Pharmaceuticals, Zealand Pharma, and Zydus Cadila.

Commenting on the report, an analyst from the research team said: “The recent shift towards untapped markets is another critical factor that will impel market growth during the forecast period. Recently, it has been observed that vendors of peptide therapeutics are moving to developing economies due to the presence of large population groups and clinical trial subjects.”

According to the report, recent advances in peptide synthesis technology will be the key driver for the growth of this market. Among all the methods of peptide synthesis, chemical and enzymatic syntheses are the most important. The synthesis of peptides has integrated structure-activity relationships (SARs) and analog generations to increase bioavailability, reduce adverse effects, increase the safety and efficacy of drugs, impart protease resistance, and develop formulations.

Further, the report states that the high cost of therapy; however, will hinder the market growth. As peptide drugs are expensive, few people opt for this mode of treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Eli Lilly
- Novo Nordisk
- Sanofi
- Takeda Pharmaceutical
- Teva Pharmaceuticals
- AbbVie
- Advanced Accelerator Applications
- Akashi Therapeutics
- Amgen
- Anthera Pharmaceuticals
- AstraZeneca
- Bachem
- Bristol-Myers Squibb
- Cardiorentis
- Corden Pharma International
- Debiopharm
- Derma Sciences
- GlaxoSmithKline
- Hanmi Pharmaceutical
- Insmed
- Ipsen
- Johnson & Johnson
- Lonza
- Mallinckrodt
- MolMed
- Merck
- Novartis
- Nymox Pharmaceutical
- Par Pharmaceuticals
- PeptiDream
- Polypeptide Group
- Radius Health
- Repligen
- Roche
- SciClone
- Shire
- The Medicines Company
- Transition Therapeutics
- X-Gen Pharmaceuticals
- Zealand Pharma
- Zydus Cadila.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll